1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  

This page is powered by Blogger. Isn't yours?

Monday, July 4, 2016

 

Alzheimer’s Disease First Steps Revealed by Mouse Brain in a Dish
































Using slices of mouse brain tissue kept alive in a lab dish, scientists have identified the earliest molecular changes leading to Alzheimer’s disease.

The findings, showing how early alterations in brain amyloid-β balance causes nerve connections called synapses to die, might allow scientist to target the mechanisms and develop therapies to prevent or postpone disease.

Once a patient receives an Alzheimer’s diagnosis, extensive brain changes involving deposits of amyloid-β protein, referred to as plaque, are already present.

Identifying the first steps leading to Alzheimer’s is a crucial step towards the development of a drug capable of this task. Until now, science has been hampered by poor models of the disease, studying brains of deceased patients or mice bred to mimic human brain conditions.

The new method, developed by researchers at Babraham Institute is a big advance, allowing researchers to track changes as they occur in real-time. Because the tissue in the dish retains its three-dimensional structure and function, it is likely to react similarly to a living brain when exposed to drugs or other experimental conditions.

The study, “Synaptophysin depletion and intraneuronal Aβ in organotypic hippocampal slice cultures from huAPP transgenic mice,” published in the journal Molecular Neurodegeneration and supported by the non-profit organization Alzheimer’s Research U.K., used a brain region called the hippocampus, involved in memory and emotional processes.

The research team isolated brain tissue from young mice engineered to develop Alzheimer’s disease as they grew old. Keeping the tissue alive in a dish, researchers noted that amyloid-β began to build up in the brain slice as it grew older. The buildup of protein could be linked to a loss of proteins in synaptic connections, crucial for the transmission of nerve signals.

Treating the slices with a drug lowered the amount of amyloid-β and restored synaptic protein production. The findings show the value of such a model system for screening potential drug candidates.

“This technique will help us to observe the earliest, usually hidden, stages of Alzheimer’s disease (while) providing an accessible system for the identification of promising treatments,” said Claire Harwell, a Ph.D. student at the Babraham Institute and first author on the paper, in a press release. “For effective therapeutics to be developed, we must understand and target the disease at its earliest stages.”

Senior study author Michael Coleman, research group leader at the Babraham Institute and professor of Neuroscience at the John van Geest Centre for Brain Repair, said the system lets candidate drugs be readily delivered and the effect monitored closely.

“Thus (we are) filling a vital gap between cell culture and animal studies. We expect that this approach will be extremely useful in research into Alzheimer’s disease and potential treatments,” Coleman said.

Dr. Simon Ridley, Director of Research at Alzheimer’s Research U.K.,  said the development of new treatments for Alzheimer’s requires innovative research techniques that include using brain tissue in a lab dish – because the human brain is a very inaccessible organ.

“It’s important for scientists to use a range of approaches to understand different aspects of Alzheimer’s and this new research provides a window into some of the early stages of the disease process. Research such as this has the power to open new doors to studies in humans and to help in the search for new treatments for this devastating disease,” Ridley said.

According to a 2015 trajectory report by the Alzheimer’s Association, about 13.5 million people could have Alzheimer’s disease in 2050. If treatments were made available that could delay the disease by five years, only 7.9 million would be affected.

Story Source: The above story is based on materials provided by ALZHEIMERSNEWSTODAY
Note: Materials may be edited for content and length